The DTWD2 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Huh-7 human hepatocellular carcinoma cell line, designed to disrupt DTWD2 gene expression. This loss-of-function model enables investigation of DTWD2??s role in liver cancer biology. The polyclonal population comprises a heterogeneous mix of edited cells generated via CRISPR/Cas9-mediated gene disruption, avoiding single-cell cloning artifacts and providing a pooled knockout representation suitable for robust functional studies.
The Huh-7 cell line, an epithelial model from human hepatocellular carcinoma, is widely used in liver cancer research for studying tumor biology, drug response, and signaling pathways. It retains malignant characteristics including abnormal proliferation, apoptosis resistance, and tumorigenicity in xenografts, making it a relevant functional genomics platform. Its epithelial origin and malignant properties allow assessment of changes in cell growth, migration, and invasion upon genetic perturbation, providing a pathophysiologically relevant context for uncharacterized genes like DTWD2.
DTWD2 (DTW domain-containing protein 2) is an uncharacterized protein harboring a DTW domain, a structural module often implicated in nucleic acid metabolism and nucleotide binding. Domains of this family are found in enzymes such as tRNA nucleotidyltransferases and poly(A) polymerases, hinting at a potential role in RNA-related processes. However, the precise molecular function, regulatory inputs, and downstream outputs of DTWD2 are unknown; no upstream regulators, downstream targets, or interacting factors have been identified, and it has not been assigned to any canonical signaling pathway. The DTWD2 knockout in Huh-7 cells thus provides an essential tool to uncover its interaction network and biological activities through approaches like quantitative proteomics and RNA sequencing.
Given DTWD2??s uncharacterized status and expression in hepatocellular carcinoma, these knockout cells offer a valuable system for probing novel liver cancer factors. Disrupting DTWD2 in a malignant hepatic background permits investigation of altered cancer phenotypes??such as proliferation, apoptosis evasion, and metastatic potential??potentially revealing hepatocarcinogenesis-related roles. The polyclonal design minimizes clonal selection biases while preserving a gene-disrupted state, aiding identification of DTWD2-dependent vulnerabilities that could suggest future therapeutic strategies.
This knockout model supports functional characterization of DTWD2, liver cancer studies, and discovery of new regulatory mechanisms. Typical assays include western blotting and RT-qPCR for validating gene disruption and profiling downstream expression changes, proliferation and apoptosis assays for growth/survival phenotypes, migration/invasion assays to assess metastatic behavior, and RNA-seq for transcriptomic analysis. Drug sensitivity assays can also evaluate whether DTWD2 loss alters chemosensitivity. These polyclonal knockout cells serve as a powerful tool for dissecting DTWD2??s role in cancer biology and for drug target validation. For further information, contact Ascent Research.
